Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib vs Interferon-Alfa in First-Line Metastatic RCC
NCT00083889Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2004
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of sunitinib in renal cell carcinoma (RCC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-Free Survival. Started Aug 2004; status: completed.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00083889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083889.